Rigel Pharmaceuticals, Inc. (RIGL)
| Market Cap | 566.35M |
| Revenue (ttm) | 144.12M |
| Net Income (ttm) | -7.73M |
| Shares Out | 170.19M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 635,489 |
| Open | 3.33 |
| Previous Close | 3.33 |
| Day's Range | 3.27 - 3.37 |
| 52-Week Range | 2.36 - 5.50 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 8.33 (+154.0%) |
| Est. Earnings Date | Nov 4, 2021 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatme...
Financial Performance
In 2020, RIGL's revenue was $108.62 million, an increase of 83.21% compared to the previous year's $59.29 million. Losses were -$29.74 million, -55.54% less than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is 8.33, which is an increase of 153.96% from the latest price.
News
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 8, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported the grant of stock options to purchase an aggregate of 469,000 shares of common stock ...
Rigel to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean S...
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical I...
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of f...
Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?
More data is needed.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such inves...
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Rigel Stock Falls After Update From COVID-19 Program
The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL) that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization (EUA). Rigel subm...
Rigel Pharmaceuticals Provides Update on COVID-19 Program
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clin...
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 27.27% and 18.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 3, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2021, including sales of TAVAL...
Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close on T...
3 Biotech Stocks That Could Rocket Higher
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
SOUTH SAN FRANCISCO, Calif., July 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodi...
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
SOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor,...
Rigel to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedule...
Rigel Appoints Alison L. Hannah, M.D.
SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L.
Rigel Pharmaceuticals (RIGL) Tops Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALI...
Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on W...
Why Rigel Pharmaceuticals Stock Jumped Today
The company announced positive results from an important COVID-19 clinical study.
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized P...
SOUTH SAN FRANCISCO, Calif., April 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate t...